Financial Reports Latest Updates Industry Maps Economic Calendar

Larimar Therapeutics, Inc. (LRMR) Annual Reports

Q: Where can I read Larimar Therapeutics, Inc. (LRMR) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Larimar Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1374690 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Operating income	$-34.4M	$-27.8M	-23.6%
Net income	$-32.8M	$-26.2M	-25.2%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 0 mn Net income -32.8 mn

Show table：Income statement

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating income	-13.8	—	-2.97	-3.52	-3.76	-4.52	-5.99	-14.4	-10.7	-13.2	-17.6	-19.7	-23.3	-17.9	-15.1	-14.8	-10.5	-13.3	-13.5	-12.8	-13.4	-15.7	-15.6	-15.2	-14.7	-13.3	-12.2	-12.9	-7.28	-3.56	-11.4	-10.3	-14.4	-12.1	-12.5	-16.7	-9.09	-8.89	-8.69	-8.51	-10.4	-7.64	-9.62	-10.3	-14.2	-16.7	-24.6	-18.3	-31.3	-31.2	-27.8	-49.5	-64.0	-31.1	-34.4
Net income	-13.9	—	-3.14	-3.50	-3.85	-4.46	-6.40	-14.7	-10.9	-13.5	-17.8	-19.9	-23.2	-17.7	-15.0	-14.7	-10.4	-13.0	-13.3	-12.6	-13.1	-16.0	-15.8	-15.1	-14.6	-13.1	-12.1	-12.9	-7.25	-3.60	-11.3	-10.3	-14.2	-12.1	-12.6	-16.8	-9.13	-8.94	-8.67	-8.32	-9.43	-6.53	-8.37	-9.06	-13.0	-14.7	-21.6	-15.5	-28.8	-29.3	-26.2	-47.7	-62.5	-29.6	-32.8

Balance sheet

Quarterly · In mn (USD)

Total assets 165 mn Total liabilities 37.9 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	37.4	—	137	129	117	236	222	206	188	169	153	142	131	119	108	95.7	105	91.4	78.0	131	121	107	94.0	83.4	71.5	64.7	119	108	98.0	86.1	74.0	81.3	72.2	64.9	56.7	127	121	113	106	98.5	90.2	231	231	213	195	165	146	183	142	205	161
Total assets	—	—	—	—	38.1	—	137	130	118	237	223	207	189	170	155	143	132	119	109	96.3	106	92.6	79.8	132	122	110	104	92.9	80.7	73.7	125	114	105	93.0	80.9	87.9	78.7	71.2	62.9	133	126	119	112	104	95.9	248	237	219	200	170	150	187	146	209	165
Current liabilities	—	—	—	—	2.92	—	4.10	11.6	6.90	9.53	11.6	13.6	16.5	12.9	10.6	11.3	9.89	8.60	9.22	7.03	7.29	7.46	9.28	11.2	13.3	13.7	13.5	16.3	12.2	9.87	6.65	5.18	8.99	8.38	7.69	10.3	8.85	8.87	7.72	9.42	10.7	8.01	7.28	6.56	9.51	12.8	21.2	16.3	24.4	22.1	26.6	45.1	64.8	47.8	34.2
Total liabilities	—	—	—	—	2.92	—	11.6	18.4	13.1	15.1	16.4	17.8	20.0	15.6	12.6	12.5	9.89	8.60	9.22	7.03	27.3	27.6	27.8	28.0	28.5	27.8	31.8	33.0	27.1	23.0	12.9	11.3	15.0	14.2	13.4	15.9	14.3	14.1	12.8	14.3	15.5	12.7	11.8	11.2	14.2	17.4	25.8	20.6	28.4	25.9	30.1	48.3	67.8	50.5	37.9
Equity	-54.7	—	—	—	-68.6	—	125	111	104	222	206	190	169	154	142	130	122	111	99.6	89.2	78.2	65.0	52.0	104	93.3	82.4	72.1	59.9	53.6	50.7	113	103	89.7	78.8	67.5	72.1	64.4	57.1	50.1	119	111	106	99.9	92.7	81.7	231	211	198	172	144	120	139	78.1	158	127

Cash flow

Quarterly · In mn (USD)

Operating -44.0 mn Investing -40.9 mn Financing -0.43 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-13.6	—	-7.43	-3.44	-4.13	-4.02	-6.23	-6.28	-11.7	-11.1	-14.4	-16.1	-17.9	-17.8	-14.5	-11.0	-8.67	-11.7	-10.2	-12.1	-9.84	-13.3	-13.3	-13.1	-11.8	-12.5	-10.8	-7.73	-9.81	-4.62	-16.5	-11.2	-9.86	-11.2	-10.8	-12.2	-7.92	-7.53	-7.49	-5.88	-6.67	-7.55	-7.36	-9.20	-9.34	-10.4	-14.0	-24.6	-21.8	-26.5	-19.4	—	-67.3	-44.6	-44.0
Investing	0	—	-0.01	0	-0.01	0	-0.06	-0.03	-57.2	-69.7	-9.34	-28.5	15.5	14.3	3.82	16.4	16.9	8.69	14.0	0.28	12.7	18.0	8.34	-47.4	14.3	0.81	13.4	15.6	-4.56	18.2	22.4	-0.01	-23.5	5.25	19.2	-6.79	6.49	—	-35.3	-3.38	-52.2	92.3	-9.84	-46.4	-2.63	-68.4	-63.5	27.3	19.2	14.4	18.8	—	67.0	29.0	-40.9
Financing	22.1	—	5.96	-0.16	34.8	6.99	102	-0.89	0	130	0.36	-0.16	-0.68	-0.66	-0.73	-0.58	-0.76	-0.73	-0.71	-0.72	18.7	0.26	-0.02	64.9	1.76	0.1	-1.82	-1.78	-1.76	-1.81	95.3	-0.13	0.24	—	—	19.9	0	—	—	75.6	-0.32	—	—	0.03	0	162	-0.33	0.03	0.04	—	0	—	65.1	108	-0.43
Cash at period end	9.94	—	8.45	4.85	35.5	38.5	134	127	58.1	107	83.6	38.8	35.6	31.4	20.0	24.9	32.4	28.6	31.7	19.2	40.8	45.7	40.7	45.1	49.3	36.4	37.2	43.3	27.2	39.0	113	101	68.2	62.2	70.6	71.5	70.1	62.6	19.7	86.0	26.8	112	94.3	38.7	26.8	110	32.3	35.1	33.2	21.1	20.6	90.1	85.4	178	92.7

Returns & leverage

Quarterly · %

ROE -139.6% ROA -109.5% Debt ratio 22.9%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	-14.5%	-26.4%	-203.4%	-20.5%	-34.3%	-41.2%	-54.3%	-41.8%	-43.5%	-44.1%	-39.8%	-40.1%	-42.6%	-45.0%	-52.0%	-62.5%	-75.7%	-62.0%	-71.6%	-79.4%	-88.4%	-64.4%	-61.8%	-53.9%	-38.0%	-39.9%	-55.0%	-74.0%	-54.6%	-63.8%	-65.7%	-69.9%	-74.1%	-36.8%	-40.3%	-40.3%	-43.5%	-31.6%	-38.4%	-26.8%	-37.5%	-44.5%	-63.6%	-50.8%	-60.3%	-78.2%	-132.6%	-109.8%	-139.6%
ROA	—	—	—	—	—	—	-13.3%	-22.7%	-46.9%	-19.2%	-31.6%	-36.8%	-48.5%	-38.6%	-40.2%	-40.3%	-36.1%	-36.7%	-39.0%	-41.3%	-43.9%	-51.9%	-60.9%	-52.5%	-54.0%	-57.7%	-59.8%	-46.9%	-44.9%	-39.0%	-30.6%	-31.4%	-42.5%	-57.5%	-47.6%	-55.2%	-55.2%	-57.8%	-60.6%	-31.7%	-34.5%	-34.6%	-37.4%	-28.2%	-33.2%	-24.6%	-33.4%	-40.1%	-54.4%	-45.5%	-51.5%	-65.0%	-95.8%	-87.7%	-109.5%
Debt ratio	—	—	—	—	7.6%	—	8.4%	14.2%	11.1%	6.4%	7.4%	8.6%	10.6%	9.2%	8.1%	8.8%	7.5%	7.2%	8.5%	7.3%	25.9%	29.8%	34.8%	21.2%	23.4%	25.3%	30.6%	35.5%	33.6%	31.1%	10.3%	9.9%	14.3%	15.3%	16.6%	18.1%	18.1%	19.8%	20.4%	10.8%	12.3%	10.7%	10.6%	10.8%	14.8%	7.0%	10.9%	9.4%	14.2%	15.2%	20.1%	25.8%	46.5%	24.2%	22.9%

EPS

Quarterly · US$

EPS US$-0.61

Show table：EPS

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-1.21	-0.64	-0.88	-0.76	-0.79	-0.92	-0.47	-0.49	-0.47	-0.37	-0.05	-0.15	-0.19	-0.21	-0.29	-0.27	-0.34	-0.24	-0.46	-0.46	-0.41	-0.61	—	—	—

Revenue & profit

Year-to-date · In mn (USD)

Revenue 0 mn Net income -62.4 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 165 mn Total liabilities 37.9 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -88.6 mn Investing -11.9 mn Financing 108 mn

Positive = cash in, negative = cash out.

Returns & leverage

Year-to-date · %

ROE -139.6% ROA -109.5% Debt ratio 22.9%

EPS

Year-to-date · US$

EPS US$-1.48

Revenue & profit

Annual · In mn (USD)

Revenue 0 mn Net income -166 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	0	0	0	0	0	0	0	—	—	—	—	—	—
Operating income	—	-35.5	-73.8	-58.2	-53.0	-61.1	-45.6	-39.7	-50.5	-36.5	-41.8	-90.9	-172
Net income	—	-36.5	-74.3	-57.9	-52.0	-61.4	-45.4	-39.4	-50.6	-35.4	-37.0	-80.6	-166

Balance sheet

Annual · In mn (USD)

Total assets 146 mn Total liabilities 67.8 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	37.4	117	188	131	105	121	71.5	98.0	72.2	121	90.2	195	142
Total assets	38.1	118	189	132	106	122	80.7	105	78.7	126	95.9	200	146
Current liabilities	2.92	6.90	16.5	9.89	7.29	13.3	12.2	8.99	8.85	10.7	9.51	24.4	64.8
Total liabilities	2.92	13.1	20.0	9.89	27.3	28.5	27.1	15.0	14.3	15.5	14.2	28.4	67.8
Equity	-68.6	104	169	122	78.2	93.3	53.6	89.7	64.4	111	81.7	172	78.1

Cash flow

Annual · In mn (USD)

Operating -70.8 mn Investing -85.4 mn Financing 162 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-28.2	-59.5	-52.0	-43.8	-51.5	-40.8	-42.2	-42.1	-27.6	-33.5	-70.8	—
Investing	—	-57.3	-92.1	51.5	35.6	-6.87	25.3	17.1	24.2	—	33.4	-85.4	—
Financing	—	108	129	-2.71	16.6	66.9	-5.26	93.6	—	—	—	162	—
Cash at period end	35.5	58.1	35.6	32.4	40.8	49.3	27.2	68.2	70.1	26.8	26.8	33.2	85.4

Returns & leverage

Annual · %

ROE -132.6% ROA -95.8% Debt ratio 46.5%

Show table：Returns & leverage

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-203.4%	-54.3%	-39.8%	-52.0%	-71.6%	-61.8%	-55.0%	-65.7%	-40.3%	-38.4%	-63.6%	-132.6%
ROA	—	-46.9%	-48.5%	-36.1%	-43.9%	-54.0%	-44.9%	-42.5%	-55.2%	-34.5%	-33.2%	-54.4%	-95.8%
Debt ratio	7.6%	11.1%	10.6%	7.5%	25.9%	23.4%	33.6%	14.3%	18.1%	12.3%	14.8%	14.2%	46.5%

EPS

Annual · US$

EPS US$-1.31

Show table：EPS

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	—	-2.94	-1.38	-0.84	-1.31	—

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Larimar Therapeutics, Inc. (LRMR) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.